Hypermutability in Carcinogenesis

Corresponding author: Bernard S. Strauss, Department of Molecular Genetics and Cell Biology, The University of Chicago, 920 E. 58th St., Chicago, IL 60637, bs19{at}midway.uchicago.edu (E-mail).

The presence of numerous chromosomal changes and point mutations in tumors is well established. At least some of these changes play a role in the development of the tumors. It has been suggested that the number of these genetic changes requires that tumorigenesis involves an increase in mutation rate. However, the presence of numerous changes can also be accounted for by efficient selection. What is required to settle the issue is some measure of nonselected mutations in tumors. In order to determine whether the tumor suppressor TP53 (coding for the protein p53) is hypermutable at some stage of carcinogenesis, the frequency of silent and multiple mutations in this gene has been examined. Silent mutations make up ~3% of the total recorded but constitute 9.5% of the mutations found in tumors with multiple mutations. Multiple closely linked mutations are also observed. Such multiple mutations suggest the operation of an error-prone replication process in a subclass of cells. The published data indicate that TP53 is hypermutable at some stage of tumor development. It is not yet clear whether TP53 is unique or whether other genes display a similar pattern of silent and multiple mutations.

This article has been cited by other articles:

				M. H. Tomasson, Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. McLellan, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia Blood, May 1, 2008; 111(9): 4797 - 4808. [Abstract] [Full Text] [PDF]

				J. W. Drake, A. Bebenek, G. E. Kissling, and S. Peddada Clusters of mutations from transient hypermutability PNAS, September 6, 2005; 102(36): 12849 - 12854. [Abstract] [Full Text] [PDF]

				K. Felix, A. Polack, W. Pretsch, S. H. Jackson, L. Feigenbaum, G.-W. Bornkamm, and S. Janz Moderate Hypermutability of a Transgenic lacZ Reporter Gene in Myc-Dependent Inflammation-Induced Plasma Cell Tumors in Mice Cancer Res., January 15, 2004; 64(2): 530 - 537. [Abstract] [Full Text] [PDF]

				P. Hainaut and G. P. Pfeifer Patterns of p53 G{->}T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke Carcinogenesis, March 1, 2001; 22(3): 367 - 374. [Abstract] [Full Text] [PDF]

				S. N. Rodin and A. S. Rodin Human lung cancer and p53: The interplay between mutagenesis and selection PNAS, October 12, 2000; (2000) 180320897. [Abstract] [Full Text]

				A. Baross-Francis, M.K. Milhausen, S. E. Andrew, G. Jevon, and F. R. Jirik Tumors arising in DNA mismatch repair-deficient mice show a wide variation in mutation frequency as assessed by a transgenic reporter gene Carcinogenesis, June 1, 2000; 21(6): 1259 - 1262. [Abstract] [Full Text] [PDF]

				H. Nozawa, E. Oda, K. Nakao, M. Ishihara, S. Ueda, T. Yokochi, K. Ogasawara, Y. Nakatsuru, S. Shimizu, Y. Ohira, et al. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53 Genes & Dev., May 15, 1999; 13(10): 1240 - 1245. [Abstract] [Full Text]

				S. N. Rodin and A. S. Rodin Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells PNAS, September 29, 1998; 95(20): 11927 - 11932. [Abstract] [Full Text] [PDF]

				G. J. McKenzie, R. S. Harris, P. L. Lee, and S. M. Rosenberg The SOS response regulates adaptive mutation PNAS, June 6, 2000; 97(12): 6646 - 6651. [Abstract] [Full Text] [PDF]

				S. N. Rodin and A. S. Rodin Human lung cancer and p53: The interplay between mutagenesis and selection PNAS, October 24, 2000; 97(22): 12244 - 12249. [Abstract] [Full Text] [PDF]